San Diego-based mostly Viking Therapeutics marked alone as a significant competitor inside the weight loss drug market in February after revealing promising data from the mid-phase demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when presented as a weekly injection and in March the company unveile